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Summary.-The formation of cyclic AMP was studied in normal liver, subcutaneous
hepatomas derived from MH1C1 cells, and premalignant liver and primary hepa-
tomas induced by the carcinogens 2-acetylaminofluorene (AAF) and 4-dimethyl-
amino-azobenzene (DAB). While only very slight effects of prostaglandins (PG)
were seen in slices of normal liver, all the hepatomas responded strongly to PGE1
and PGE2. The hepatomas also had increased PGE,-sensitive adenylate-cyclase
activity. PGFia and PGF2as did not increase the cAMP level significantly either in the
liver or in the hepatomas. During AAF carcinogenesis the response to PGE1 increased
slightly during the carcinogen feeding, and was greatly elevated only in the fully
developed hepatomas. This is in contrast to the increase in adrenalin response seen
during carcinogenesis, which starts much earlier, and reaches a peak value within
8-10 weeks. It is concluded that various hepatomas have elevated responsiveness
to PGE1 and PGE2 as well as to adrenalin, but the course of change in the tissues'
ability to respond to these agents during carcinogenesis is very different.
CYCLIC AMP (cAMP) seems to be a
regulator of cell growth, but its precise
role is incompletely understood (Ryan &
Heidrick, 1974; Pastan et al., 1975;
Friedman, 1976). The metabolism of
cAMP is altered in many cancers and
malignant cell lines. In rat hepatomas
the cAMP system is regulated differently
from that of normal liver tissue. In most
hepatomas adenylate cyclase is less re-
sponsive to glucagon than the liverenzyme
(Allen et al., 1971; Emmelot & Bos, 1971;
Christoffersen et al., 1972; Tomasi et al.,
1973; Boyd et al., 1974; Hickie et al.,
1975; Criss & Morris, 1976; Hickie et al.,
1977). However, increased effects ofadren-
alin (Brown et al., 1970; Christoffersen
et al., 1972; Boyd et al., 1974) and prosta-
glandin E1 (PGE1) (Chayoth et al., 1973)
have also been described. Furthermore,
during treatment of rats with chemical
carcinogens, before tumour development,
alterations in the response pattern of the
adenylate cyclase have been observed,
including increased responsiveness to
adrenergic agents (Christoffersen et al.,
1972, 1974; Christoffersen, 1975; Boyd
et al., 1974, 1976) and to PGE1 (Chayoth
et al., 1973).
The present study was undertaken in
order to get more information on how
control of cAMP formation differs in
hepatomas and livers. Particular interest
has been devoted to the effect of prosta-
glandins, which have also been proposed as
taking part in growth regulation (Sykes,
1976; Jimenez de Asua et al., 1975; Hial et
al., 1976). Some primary and transplanted
hepatomas were studied, to see whetherthe
increased responsiveness to PGE1 that has
been reported for ethionine-induced hepa-
tomas (Chayoth et al., 1973) is present also
in other hepatomas, and also includes
other prostaglandins. We also wanted to
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examine the time course of the changes in
responsiveness of the liver tissue towards
PGE1 and hormones during chemical
carcinogenesis.
MATERIALS AND METHOI)S
Materials.-2-Acetylaniinofluorene (AAF)
and 4-dimethylaminoazobenzene (DAB)
were obtained from Koch-Light Laboratories,
UK, adrenalin bitartrate from Rhone Poulenc
Paris, glucagon from, Novo, Copenhagen,
cyclic AMP, theophylline and pyruvate kinase
from SigmaChemical Co.,StLouis, Mo,U.S.A.,
methylisobutylxanthine from Aldrich Chemi-
cals, Milwaukee,Wise.,U.S.A., cyclic[3H]AMP
(24-1 Ci/-mmol) from Newx England Nuclear,
Boston, U.S.A., [ac32P]ATP from The Radio-
chemical Centre, Amersham, and phosphoenol
pyruvate from Boehringer, Mannheim Germ-
any. The prostaglandins Mwere kindly provided
by Dr John Pike, Thie Upjohln Company,
Kalanmazoo, Mich., U.S.A.
Carcinogen treatment.-Male albino XVistar
rats, 12 wseeks old at the beginning of the
carcinogen treatmient, were used. The anii-
mals were fed a basal diet (Christoffersen,
1975). This diet was supplemented with
0-0250o AAF for the treated group. Pair-
fed control animals received the basal diet.
Liver tissue designated as pre-malignant
was taken from rats killed at various
times of treatment, before development of
tumours. After 8 inonths the carcinogen
treatment was terminated, and the animals
were given standard laboratory chowt, until
they were killed 5 months later. At that
time, the mnajority of treated rats had liver
tumours, often multiple nodules of varying
diameter. Tunmours of diameter 0-5-1P5 cm
were used in the experiments described here.
The ttamours were examined histologically
(courtesy of Dr S. B. Refsum, Rikshospitalet,
Oslo), and were found to be hepatocareino-
mnas. We also studied a single tumour from a
rat treated wiith 0-0500 DAB for 7 months,
followed by 9 months on carcinogen-free
diet.
Inoculation of hepatoma cells.-Buffalo rats
of either sex xwere used in these experi-
ments. The clonal rat hepatoma cell line
MH1C1 derived from Morris hepatoma 7795
(Richardson et al., 1969) was cultured as
described by Gaudernack et al. (1973).
When the rats wN-ere about 2 weeks old,
suspensions of MH1C1 cells containing
200 pg cell protein suspended in 0-5 ml
growth medium (Dulbecco modified Eagle's
medium) were inoculated into each flank
at the lower back region. After 2-5 months,
when tumours of diameter 1-2 cm had
developed, the animals were killed.
Cyclic AMP accumulation in slices.-The
rats were anaesthetized with ether, and the
livers and tumours were rapidly excised and
transferred to ice-cold buffer. The hepatomas
were trimmed of connective tissue and
necrotic areas were removed. The tissues
were cut into 0-4-0 5 mm-thick slices weigh-
ing 20-80 mg. The slices were transferred
to 10-ml Erlenmeyer flasks, and preincubated
45-60 min at 37°C in 1-5 ml Krebs-Ringer
bicarbonate buffer containing 119-2mM NaCl,
3mM KCI, 1-2mM MgSO4, 2-4mM KH2PO4,
24-9mM NaHCO3, 2-0mM CaC12 and 10mMl
glucose, under continuous gassing with 950%
02 and 50 CO2. The incubation was initiated
by the addition of the agents to be tested
dissolved in 0-5 ml of the Krebs-Ringer
bicarbonate buffer with 8mM theophylline,
to give a final volume of 2 ml, and concentra-
tions as indicated in the figure legends.
Stock solutions of prostaglandins were dis-
solved in 96% ethanol (2 mg/ml) and diluted
in buffer immediately before addition. The
incubation was terminated by rapidly trans-
ferring the slice to liquid N2 after blotting on
filter paper.
The frozen slices were homogenized in
500 trichloroacetic acid. Cyclic AMP was
determined as described earlier (Christoffer-
senet al., 1973) using theprotein-binding assay
of Gilman (1970).
Assay of adenylate-cyclase activity. Incu-
bations were carried out at 30°C in 200 t1
of a mixture containing: lmM [oa32P]ATP
( 106 Ct/min tube), 1mm cAMP, 4mM MgCl2,
30mm KCI, 50mM Tris-HCl, pH 7*5, 1mM
metllylisobutylxanthine, 1-5 i.u. pyru-
vate kinase, 2-5mM phosphoenol pyruvate,
and homogenate equivalent to about 500 Hig
protein. The reaction was terminated by the
addition of 400 ,ul 150mM ZnSO4. 50 ,ul
[3H]cAMP ( - 2500 ct/min) for recovery
determination during the purification step
and 400 ,ul 150mAit Na2CO3 wNere added to
each tube. After centrifugation at 2000 g for
5 min, the labelled cAMP in the supernatants
was purified by the Dowex-50/alumina
double-column method described by
Salomon et al. (1974), aind counted by
liquid scintillation.CYCLIC AMP IN HEPATOMAS AND LIVER
Determination of protein. The method of
LowNrry et al. (1951) was used.
RESULTS
Hormnone and prostaglandin ef.fects on
cAMP levels in slices fronm Iiver and
hepatomas
Table I shows the levels of cAMP in
slices from various hepatomas after ex-
posure to adrenalirn, glucagon or PGE1.
In one series of experiments, MH11C1-
derived tumours were compared with liver
from tumour-bearing animals. In the
liver slices neither adrenalin nor PGE1
showed any effect, while glucagon in-
creased the cAMP level about 5-fold in
2 min. In contrast, the slices prepared
from subcutaneous MH1Cl-derived hepa-
tomas or mesenterial metastases from
these tumours responded strongly to
adrenalin (4-5-fold) and to PCE1 (10-
fold), but only slightly to glucagon (40%0
increase).
Similarly, primary hepatomas, induced
by AAF or DAB feeding, responded very
strongly to adrenalin or PGE1, compared
to the slight effects of these agents on the
cAMP content in slices from the adjacent
uninvolved liver tissue. These primary
hepatomas differed from the MHlCl-
derived tumours in that most of them
were markedly responsive to glucagon.
Dose-response curves for various prosta-
glandins on cAMP levels in slices from
liver and MH1C1-derived tumours are
given in Fig. 1. The figure shows the
striking difference between the liver and
the hepatoma in responsiveness to PGE1
and PGE2. PGF1a and PGF2a had no
significant effect on any of the tissues.
The cAMP content of the tumour slices
did not reach a plateau in the range of
prostaglandin concentrations used.
Evidence for increased activity of PGE1-
sensitive adenylate cyclase in the hepatomas
The adenylate cyclase in homogenates
of hepatomas responded more strongly to
PGE1 than did the enzyme from liver
(Table II). The effect of PGE1 was greater
in the hepatoma homogenates (113]0
increase over basal activity, vs 63%0 in
liver homogenates), but this effect was
much less pronounced than on the slices
from the same tumours (Table I). We
have no explanation for this discrepancy,
which was seen also for the adrenalin
TABLE I. Effect of prostaylandins and hormones on levels of cyclic AMP in slices of rat
liver and hepatornas
Tlisstle
BLffalo rats:
Livelra
IiIH 1C1 hepatomiia''
Metastatic tLMlVoUrS'
Wistar Iats:
Livela
AAF hepatoniad
pmol cAMAP/mng wset wvt. ± s.e.
No. of PGEI Adrlenalin
animals No addition (28Hto) (50yzv)
8 0-22±0-04 0 32 W-008
10 0-31 0-08 3-00 0-29
(P<0 001g)
6 0-24±0 09 3-11 0-67
(P<0*005)
:1 0-25 ±0-12 0-3:3 -0 10
5 0-64±006 ( )--93±0-87
(P< 0 .05)
0-28 0-1Of
1 35±0 -20
(P < -05)
1 -77 0-38
(P<0 05)
0-48±0-10
1-854-0-25
(P< 0 05)
Glucagon
(I -4 u-)
I 22 028 28
0 44 10 -09
(P< -001)
0-30±0- 15
(P<0- 005)
1-92 40 5:3
1 -41 ±0-22
(P<0-5) DAB hepatomae I 0 )52 1 .13 2-00 3-62
a From tumour-bearinig animal. bJ Growing subcutaneouisly from inoctula of MHtC I cells.
cAbdominal metastases from s.c. MHRC, hepatomas.
(I Primaries induced by 2-AAF feeding.
e Primary indluced by DAB feeding.
f This value represents only 4 livers.
9 The significance levels of the comparison of peicentage stimulatioin over basal in the tumoui slices aindl the corresponding stimulation in the liver slices, calculated by the Wilcoxon's two-sample test for the uin- paired case.
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FIG. 1.-Dose-response curves for the effects ofprostaglandins on cAMP accumulation in slices from MHlCl-derived hepatoma (left) and liver (right) incubated as in Methods, in the presence of the various prostaglandins and 2mM theophylline in a final volume of 2 ml. Symbols: *-PGE1;
-EO- PGE2; -v- PGF1a; -V- PGF2cX. Each point represents mean ± s.e. of determinations
on 3-6 slices.
TABLE II.-Adenylate-cyclase activity in homogenatesfrom liver and 111H1Cl-derived
hepatoma tissue
pmol cAMP/mg protein/min + s.e.
No. PGE1 Adrenalin Glucagon NaF
samples No addition (28pM) (50,UM) (14,UM) (10mM)
Livera 6 4-1±0-4 6-7+0-9 5-1±0-5 10-6±1-1 27-6±3-3 HepatoMab 6 3-9±0-7 8-3±1-0 8-1±1-4 4 8±08 42-3±2-9
(P<0
-005c) (P<0*05) (P<0*005) (P>0
- 1)
a From tumour-bearing Buffalo rats.
b s.c. hepatomas developed from inocula ofMH1C1 cells.
c The significance levels calculated as for Table I.
response (Table I vs Table II; cf. also
Christoffersen et al., 1974). It is a well-
known phenomenon that a large part of
the adenylate-cyclase response towards
hormones maybelostontissuehomogeniza-
tion (Achar et al., 1977), possibly owing
to membrane derangement or non-optimal
composition of the incubation mixture in
broken-cell preparations.
In the present case, additional evidence
that the very strong effect of PGE1 on
cAMP accumulation in the hepatoma
tissue is actually due to adenylate-
cyclase activation, was obtained in experi-
ments (Table III) showing that the
increase in cAMP content in slices after
PGE1 could be amplified by theophylline,
and even more so by the more potent
phosphodiesterase inhibitor, methyliso-
butylxanthine.
Hormone and PGE1 responsiveness during
AAF-carcinogenesis
The development of the hormone and
I
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TABLE III.-Effect of theophylline and
methylisobutylxanthine on PGE1-stimu-
lated cAMP accumulation in hepatoma
slices prepared from s.c. growing hepa-
tomas developed from inoculates of
MHlCl cells as in Materials and Methods
Addition
None
Theophylline (2mM)
Methylisobutylxanthine
(0 *5mM)
PGE1 (28,uM)
+ theophylline (2mi
+methylisobutylxantl
(O *5mM)
pmol cAMP/mg wet wt.
(Mean ± s.e. from 3
tumours)
0-23±0-04
0-31±0 04a
0-41 ±008a
1 -700- 66b
M) 2 - 78±0 *29b,c
iine
6 - 87±0 62b,c
a p > 0 1 VS basal level (no addition).
b p < 0*03 VS basal level.
c P < 0*03 VS slices exposed to PGE1 alone.
Statistical evaluation based on Wilcoxon's two-
sample test for the unpaired case.
PGE1 responsiveness in slices during
AAF-carcinogenesis is shown in Fig. 2. As
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shown previously (Christoffersen et al.,
1974), the adrenalin response increased
rapidly during the first weeks, reaching a
maximum at about 8 weeks. It then
declined, as has also been found during
3'-methyl-DAB carcinogenesis (Boyd et
al., 1974, 1976), but in the final hepatoma
the response to adrenalin was still
greater than in normal liver tissue (Fig.
2).
The PGE1 response increased slowly
during the carcinogen treatment, but
was greatly increased in the hepatomas.
This is in accordance with the observa-
tions of Chayoth et al. (1973), who found
increased response to PGE1 during ethio-
nine carcinogenesis, before and after
hepatoma development. However, in the
present work we show that the changes in
adrenalin and PGE1 response take com-
pletely different courses during the car-
cinogen treatment (Fig. 2).
0 3 8 10 15 19
WEEKS ON AAF - TREATMENT HEPATOMA
FIG. 2.-Accumulation of cAMP in slices from liver during AAF carcinogenesis and from resultant
hepatomas in response to PGE1, glucagon and adrenalin in the presence of 2mM theophylline.
Symbols -0- no addition; -*- adrenalin (50,UM); -A- glucagon (1-4,UM); -*- PGE1
(28,uM). Each point represents mean ± s.e. of determinations on separate livers or tumours, the
number of which is given in parentheses above the abscissa. Slices from control rats showed no
age-related changes in the hormone response during the treatment period. At 8 weeks control
values were: no addition 0-16 ± 0-02, adrenalin 0 40 ± 0 10, glucagon 1-77 ± 0 03, PGE1
0-38 0-08, (n = 3). At the tumour stage control values were: no addition 0-22 + 0-05, adrenalin
0-29 ± 004, glucagon 1-57 ± 0-32. PGE1 0-20 i 0-01 (n = 5).
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FIG. 3. Effects ofPGE1 and glucagon added
alone or in combination on liver slices
from rats treated with AAF. Inset; the
dose-response curve forPGE1 and glucagon.
The slices were incubated in the presence
of 2mM theophylline as described in
Methods.
The glucagon response rose temporarily
but less markedly than the adrenaline
response during carcinogenesis.
Combination of gtucagon and POE1
In an attempt to get information on
whether PGE1 acts on the same cell
population as glucagon, we tried com-
binations of these two agents, using a
supramaxial concentration of glucagon.
Although additive effects would not ex-
clude the possibility that the two agents
act on separate adenylate cyclases in a
common cell population, a lack ofadditiv-
ity would make it improbable that they
have separate target cells. These experi-
ments were done on slices from AAF-
treated animals. In these livers, before
tumour development, PGE1 added alone
increased the cAMP content 170%, and
glucagon gave about a 10-fold increase.
The cAMP content in slices exposed to
a combination ofthe two agents, however,
was lower than in slices exposed to
glucagon alone. Inhibition by PGE1 of
the effect of glucagon on cAMP has
previously been demonstrated by De-
Rubertis et at. (1974) in liver in vivo. We
have seen that PGE1 also inhibits the
effect of adrenalin on cAMP in hepato-
cytes (Br0nstad & Christoffersen, unpub-
lished).
DISCUSSION
The present results show that 3 different
kinds of hepatomas, and several metas-
tases from one of them, have greatly increased capacity to accumulate cAMP in
response to E-prostaglandins, apparently due to the increased effect of theseprosta- glandins on adenylate cyclase. Increased
cffect ofPGE1 on cAMPlevels oradenylate cyclase has also been observed in primary hepatomasandliverfromethionine-treated
animals (Chayoth et al., 1973). In our
experiments we found that PGE2 was also
strongly stimulatory, while PGF1a and
PGF2<, had no significant effect on the
cAMP level.
The data presented here also show that
the responsiveness to adrenalin and
PGE1 develops very differentlyduring the
carcinogenic process. It has previously been shown that during liver carcino-
genesis the adrenalin responsiveness increases during the first weeks of carcino-
gen treatment (Christoffersen et al., 1972, 1974; Boyd et al., 1974, 1976). After 7-12 weeks the responsiveness de-
creases (Boyd et al., 1974, 1976), but in
the final hepatomas the adrenalin re-
sponsiveness is still greater than in normal
liver. This pattern was confirmed in the
present study (Fig. 2). In contrast, the
increased PGE1 effect appeared much
later and was notmaximaluntilhepatomas had developed (Fig. 2). AVe do not know
exactly at which stage the increased
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PGE1 responsiveness appears. In general,
it is still not known whether changes in
cell properties seen after malignant trans-
formation result from continuous altera-
tions during the process of carcinogenesis.
The interpretation ofthe present results,
in terms of understanding the role of
prostaglandins inthebiologyofhepatomas,
is difficult at present. One problem is that
although all the hepatomas investigated
in the present study were strongly re-
sponsive to PGE1 and PGE2, we do not
know so far whether this is a property of
the hepatoma cells or of some other cell
type in the tumour. We investigated
whether the effects of PGE1 and glucagon
on premalignant liver were additive. The
interpretation of these experiments, how-
ever, was hampered by the fact that
PGE1 inhibited the glucagon effect on
cAMP accumulation, as has previously
also been seen in normal rat liver in vivo
(DeRubertis et al., 1974). Therefore, these
experiments did not give a final answer
to the important question of the cellular
localization of the increase in prosta-
glandin responsiveness in liver tissue
during hepatoma development. The role
of a prostaglandin-mediated increase of
cAMP in hepatoma cells is also unclear.
Cyclic AMP levels are high in various
hepatomas (Thomas et al., 1973; Chayoth
et al., 1972) as well as in liver tissue under
conditions of rapid proliferation, such as
in the neonatal period (Christoffersen
et al., 1973) and during regeneration
(McManus et al., 1972). Under appropriate
conditions, cAMP administration leads to
initiation of liver DNA synthesis in vivo
(Short et al., 1975). Prostaglandins have
been proposed as positive as well as
negative regulators of cell proliferation
(Sykes, 1976; Jimenez de Asua et al., 1975;
Feher & Gridali, 1974; Thomas et al.,
1973). In foetal hepatocyte cultures,
PGE1 has been shown to enhance incor-
poration of 3H-thymidine into DNA
(Leffert et al., 1976). Increased responsive-
ness to prostaglandins could therefore
play a role in the phenotypic expression
of the malignant state of some cancers.
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